Shifting phenotype and differentiation of CD11b
Chronic inflammation
Myeloid derived cells
NFAT1
Psoriasis
RORγt
T cells
Journal
Inflammation research : official journal of the European Histamine Research Society ... [et al.]
ISSN: 1420-908X
Titre abrégé: Inflamm Res
Pays: Switzerland
ID NLM: 9508160
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
22
02
2024
accepted:
09
07
2024
revised:
19
06
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
aheadofprint
Résumé
The exact immunological mechanism of widespread chronic inflammatory skin disorder psoriasis has not been fully established. CD11b The status of T cells and MDACs; their functionality and differentiation properties, and the roles of RORγt and NFAT1 in MDACs were evaluated using flow cytometry, qRT-PCR and confocal imaging. We found gradual increase in T cells and MDACs and an increase in the number of IL17 -secreting MDACs and T cells in the skin of psoriatic animals. We also noted that MDAC differentiation is biased toward M1 macrophages and DCs which perpetuate inflammation. We found that psoriatic MDACs were unable to suppress T-cell proliferation or activation but seemingly helped these T cells produce more IL17. Inhibition of the RORγt/NFAT1 axis in MDACs increased the suppressive nature of MDACs, allowing these cells to suppress the activity of psoriatic T-cells. Our results indicate that altered MDAC properties in psoriatic condition sustains pathological inflammation and RORγt and NFAT1 as promising intervention target for psoriasis management.
Identifiants
pubmed: 39052064
doi: 10.1007/s00011-024-01918-0
pii: 10.1007/s00011-024-01918-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Council for Scientific and Industrial research, India
ID : 09/1156(0002)/2017-EMR-I
Organisme : University Grants Commission
ID : 688/(CSIR-UGC NET DEC. 2017)
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Sarkar D, Gorai P, Pramanik A, Mondal A, Mondal N, Modak B, et al. Characterization and active component identification of Premna herbacea roxb root extract reveals anti-inflammatory effect and amelioration of imiquimod induced psoriasis via modulation of macrophage inflammatory response. Phytomedicine. 2023;119:155007. https://doi.org/10.1016/j.phymed.2023.155007 .
doi: 10.1016/j.phymed.2023.155007
pubmed: 37549537
Deng J, Tan S, Liu R, Yu W, Chen H, Tang N, et al. Chinese medicine formula PSORI-CM02 alleviates psoriatic dermatitis via M-MDSCs and Th17 crosstalk. Front Pharmacol. 2021;11:1–13.
doi: 10.3389/fphar.2020.563433
Oka T, Sugaya M, Takahashi N, Takahashi T, Shibata S, Miyagaki T, et al. CXCL17 attenuates Imiquimod-Induced psoriasis-like skin inflammation by recruiting myeloid-derived suppressor cells and regulatory T cells. J Immunol. 2017;198:3897–908.
pubmed: 28389593
doi: 10.4049/jimmunol.1601607
Dhabale A, Nagpure S. Types of psoriasis and their effects on the Immune System. Cureus. 2022;14(9):e29536
pubmed: 36312680
pmcid: 9592057
Alrefai H, Muhammad K, Rudolf R, Pham DAT, Klein-Hessling S, Patra AK, et al. NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. Nat Commun. 2016;7:11724. https://doi.org/10.1038/ncomms11724 .
doi: 10.1038/ncomms11724
pubmed: 27222343
pmcid: 4894959
Pramanik A, Bhattacharyya S. Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment. Life Sci. 2022;305:120755. https://doi.org/10.1016/j.lfs.2022.120755 .
doi: 10.1016/j.lfs.2022.120755
pubmed: 35780842
Lim HX, Kim TS. Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers. Int J Mol Sci. 2020;21:3599.
pubmed: 32443699
pmcid: 7279333
doi: 10.3390/ijms21103599
Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021. https://doi.org/10.1038/s41577-020-00490-y .
doi: 10.1038/s41577-020-00490-y
pubmed: 33526920
pmcid: 7849958
Almand B, Clark JI, Nikitina E, Beynen V, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166(1):678–89. https://doi.org/10.4049/jimmunol.166.1.678 .
doi: 10.4049/jimmunol.166.1.678
pubmed: 11123353
Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment : expect the unexpected. J Xlin Invest. 2015;125:3356.
doi: 10.1172/JCI80005
Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021. https://doi.org/10.1038/s41392-021-00658-5 .
doi: 10.1038/s41392-021-00658-5
pubmed: 34952914
pmcid: 8703211
Mahanti K, Saha J, Sarkar D, Pramanik A, Chattopadhyay NR. Alteration of functionality and differentiation directed by changing gene expression patterns in myeloid-derived suppressor cells (MDSCs) in tumor microenvironment and bone marrow through early to terminal phase of tumor progression. J Leukocyte Biol. 2024;115:958–84.
pubmed: 38236200
doi: 10.1093/jleuko/qiae013
Liu P, Peng C, Chen X, Wu L, Yin M, Li J. Acitretin promotes the differentiation of myeloid-derived suppressor cells in the treatment of psoriasis. Front Med. 2021;8:1–13.
Chen C, Tan L, Zhu W, Lei L, Kuang Y, Liu P, et al. Targeting myeloid-derived suppressor cells is a novel strategy for anti-psoriasis therapy. Mediators Inflammation. 2020.
Fultang L, Panetti S, Ng M, Collins P, Graef S, Rizkalla N, et al. EBioMedicine MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine. 2019;47:235–46. https://doi.org/10.1016/j.ebiom.2019.08.025 .
doi: 10.1016/j.ebiom.2019.08.025
pubmed: 31462392
pmcid: 6796554
Yang Y, Li C, Liu T, Dai X, Bazhin AV. Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front Immunol. 2020;11:1–22.
Li M, Zhu D, Wang T, Xia X, Tian J, Wang S. Roles of myeloid-derived suppressor cell subpopulations in autoimmune arthritis. Front Immunol. 2018;9:1–15.
doi: 10.3389/fimmu.2018.02849
Kong YY, Wilson K, Apostolopoulos V. Dendritic cells and myeloid derived suppressor cells fully responsive to stimulation via toll-like receptor 4 are rapidly induced from bone-marrow cells by granulocyte-macrophage colony-stimulating factor. Vaccines. 2020;8:522.
pubmed: 32932705
pmcid: 7564202
doi: 10.3390/vaccines8030522
Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. 2010;7:164–74.
pubmed: 20383173
pmcid: 4002915
doi: 10.1038/cmi.2010.21
Kwon HK, Kim GC, Hwang JS, Kim Y, Chae CS, Nam JH, et al. Transcription factor NFAT1 controls allergic contact hypersensitivity through regulation of activation induced cell death program. Sci Rep. 2016;6:1–15.
doi: 10.1038/srep19453
Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997;15:707–47.
pubmed: 9143705
doi: 10.1146/annurev.immunol.15.1.707
López-Rodríguez C, Aramburu J, Rakeman AS, Rao A. NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc Natl Acad Sci USA. 1999;96:7214–9.
pubmed: 10377394
pmcid: 22056
doi: 10.1073/pnas.96.13.7214
Wang X, Bi Y, Xue L, Liao J, Chen X, Lu Y, et al. The calcineurin-NFAT axis controls allograft immunity in myeloid- derived suppressor cells through reprogramming T cell. Mol Cell Biol. 2015;35:598–609.
pubmed: 25452304
pmcid: 4285420
doi: 10.1128/MCB.01251-14
Al-Daraji WI, Grant KR, Ryan K, Saxton A, Reynolds NJ. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol. 2002;118:779–88. https://doi.org/10.1046/j.1523-1747.2002.01709.x .
doi: 10.1046/j.1523-1747.2002.01709.x
pubmed: 11982754
Herman A, Herman AP. Topically used herbal products for the treatment of psoriasis - mechanism of action, drug delivery, clinical studies. Planta Med. 2016;82:1447–55.
pubmed: 27574899
doi: 10.1055/s-0042-115177
Alarami AMJ. Histopathological changes in the liver and kidney of albino mice on exposure to Insecticide. Dimethoate Int J Curr Microbiol App Sci. 2015;4:287–300.
Saha J, Sarkar D, Pramanik A, Mahanti K, Adhikary A, Bhattacharyya S. PGE2-HIF1α reciprocal induction regulates migration, phenotypic alteration and immunosuppressive capacity of macrophages in tumor microenvironment. Life Sci. 2020;253:117731. https://doi.org/10.1016/j.lfs.2020.117731 .
doi: 10.1016/j.lfs.2020.117731
pubmed: 32353431
Lu Y, Xiao Y, Yin MZ, Zhou XC, Wu LS, Chen WQ, et al. Polyethylene glycol ointment alleviates Psoriasis-Like inflammation through down-regulating the function of Th17 cells and MDSCs. Front Med. 2021;7:1–11.
doi: 10.3389/fmed.2020.560579
Pati S, Mukherjee S, Dutta S, Guin A, Roy D, Bose S, et al. Tumor-associated CD19 þ CD39 – B regulatory cells deregulate class-switch recombination to suppress antib responses. Cancer Immunol Res. 2023;11:364–80.
pubmed: 36574614
doi: 10.1158/2326-6066.CIR-21-1073
Yousefzadehn H, Azad FJ, Rastin M, Banihashemi M, Mahmoudi M. Expression of Th1 and Th2 cytokine and associated transcription factors in peripheral blood mononuclear cells and correlation with disease severity. Rep Biochem Mol Biol. 2017;6:102–11.
Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN. Suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell. 2013;24:631–44. https://doi.org/10.1016/j.ccr.2013.10.009 .
doi: 10.1016/j.ccr.2013.10.009
pubmed: 24229710
pmcid: 3928012
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727–42.
pubmed: 32266087
pmcid: 7136921
Adamczyk M, Krasowska D. PD1 / PD-L1 pathway in psoriasis and psoriatic arthritis: a review. Adv Dermatol Allergol. 2021;38:925–30.
doi: 10.5114/ada.2021.112274
Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485–98. https://doi.org/10.1038/s41577-020-00490-y .
doi: 10.1038/s41577-020-00490-y
pubmed: 33526920
pmcid: 7849958
Bruger AM, Dorhoi A, Esendagli G, Barczyk K, Pierre K. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2018. https://doi.org/10.1007/s00262-018-2170-8 .
doi: 10.1007/s00262-018-2170-8
pubmed: 29785656
pmcid: 11028070
Du M, Zhou W, Dong L, Zhu X, He Y, Yang J, et al. Cyclosporin A Promotes Growth and Invasiveness In Vitro of Human First-Trimester Trophoblast Cells Via MAPK3 / MAPK1-Mediated AP1 and Ca 2 þ / Calcineurin / NFAT Signaling Pathways 1. Biol Reprod. 2008;1110:1102–10.
doi: 10.1095/biolreprod.107.063503
Zhang J, Zhang Y, Yang Z, Cheng D, Zhang H, Wei L, et al. Inducible nitric oxide synthase- expressing myeloid-derived suppressor cells regulated by interleukin 35 contribute to the pathogenesis of psoriasis. Front Immunol. 2023;14:1091541.
pubmed: 36969174
pmcid: 10034090
doi: 10.3389/fimmu.2023.1091541
Albanesi C. Immunology of psoriasis. Clin Immunol Princ Pract. 2019;64:871–8.
doi: 10.1016/B978-0-7020-6896-6.00064-8
Wulffen M, Von Luehrmann V, Robeck S, Hermann S, Roth J, Vogl T. Article S100A8/A9-alarmin promotes local myeloid-derived suppressor cell activation restricting severe autoimmune arthritis ll ll S100A8 / A9-alarmin promotes local myeloid-derived suppressor cell activation restricting severe autoimmune arthritis. Cell Rep. 2023;42:113006. https://doi.org/10.1016/j.celrep.2023.113006 .
doi: 10.1016/j.celrep.2023.113006
Zhao Y, Wu T, Shao S, Shi B, Zhao Y. Phenotype, development, and biological function of myeloid-derived suppressor cells. Oncoimmunology. 2016;5:1–12.
doi: 10.1080/2162402X.2015.1004983
Wegner A, Verhagen J, Wraith DC, Building BS, Pond GM, Pond GM, et al. Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease. Immunology. 2017;151:26–42.
pubmed: 28140447
pmcid: 5382345
doi: 10.1111/imm.12718
Melero-jerez C, Cristina M, Moliné-velázquez V, Clemente D. Biochimica et Biophysica Acta Myeloid derived suppressor cells in in fl ammatory conditions of the central nervous system ☆. BBA-Mol Basis Dis. 2016;1862:368–80. https://doi.org/10.1016/j.bbadis.2015.10.015 .
doi: 10.1016/j.bbadis.2015.10.015
Yan L, Liang M, Yang T, Ji J, Sanker G, Kumar J. The immunoregulatory role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis. Front Immunol. 2020;11:1–9.
doi: 10.3389/fimmu.2020.568362
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:1–17.
doi: 10.1186/s12943-018-0928-4
Vathiotis IA, Gomatou G, Stravopodis DJ, Syrigos N. Programmed death-ligand 1 as a regulator of tumor progression and metastasis. Int J Mol Sci. 2021;22:1–13.
doi: 10.3390/ijms22105383
Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1–13.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
pubmed: 22437870
pmcid: 4856023
doi: 10.1038/nrc3239
Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021. https://doi.org/10.1038/s41392-021-00670-9 .
doi: 10.1038/s41392-021-00670-9
pubmed: 34961761
pmcid: 8712507
Grohová A, Dáňová K, Adkins I, Šumník Z, Petruželková L, Obermannová B, et al. Myeloid - derived suppressor cells in type 1 diabetes are an expanded population exhibiting diverse T-cell suppressor mechanisms. PLoS One. 2020;15:1–21.
doi: 10.1371/journal.pone.0242092
Amodio G, Cichy J, Conde P, Matteoli G, Moreau A. Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation. Cancer Immunol Immunother. 2019;68:661–72. https://doi.org/10.1007/s00262-018-2264-3 .
doi: 10.1007/s00262-018-2264-3
pubmed: 30357490
Zhang J, Lin Y, Li C, Zhang X, Dai L, Wang Y, et al. IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1/M2 macrophage ratio in Psoriasis. J Immunol. 2019;197:2131.
doi: 10.4049/jimmunol.1600446
Hu P, Wang M, Gao H, Zheng A, Li J, Mu D, et al. The role of helper T cells in Psoriasis. Front Immunol. 2021;12:1–10.
doi: 10.3389/fimmu.2021.788940
Li H, Dai FU, Peng Q, Gan H, Zheng J. Myeloid-derived suppressor cells suppress CD4 + and CD8 + T cell responses in autoimmune hepatitis. Mol Med. 2015;12:3667–73.
Tu Z, Wei W, Xiang Q, Wang W, Zhang S, Zhou H. Pro-inflammatory cytokine IL-6 regulates LMO4 expression in psoriatic keratinocytes via AKT/STAT3 pathway. Immun Inflamm Dis. 2023;11:1–11.
doi: 10.1002/iid3.1104
Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130:145.
pubmed: 22677045
pmcid: 3470466
doi: 10.1016/j.jaci.2012.04.024
Zhu J, Chen S, Wu L, Wang R, Zheng S, Zhao D, et al. The expansion of myeloid-derived suppressor cells is associated with joint inflammation in rheumatic patients with arthritis. Biomed Res Int. 2018;2018:5474828.
pubmed: 30046600
pmcid: 6038685
doi: 10.1155/2018/5474828
Imura C, Ueyama A, Sasaki Y, Shimizu M, Furue Y. A novel ROR g t inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations. J Dermatol Sci. 2019;93:176–85. https://doi.org/10.1016/j.jdermsci.2019.03.002 .
doi: 10.1016/j.jdermsci.2019.03.002
pubmed: 30905492
Maguire O, Tornatore KM, O’Loughlin KL, Venuto RC, Minderman H. Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytom Part A. 2013;83:1096–104.
doi: 10.1002/cyto.a.22401
Yahia-Cherbal H, Rybczynska M, Lovecchio D, Stephen T, Lescale C, Placek K, et al. NFAT primes the human RORC locus for RORγt expression in CD4 + T cells. Nat Commun. 2019;10:1–17. https://doi.org/10.1038/s41467-019-12680-x .
doi: 10.1038/s41467-019-12680-x
Iacobaeus E, Douagi I, Jitschin R, Marcusson-Ståhl M, Andrén AT, Gavin C, et al. Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis. Immunol Cell Biol. 2018;96:820–30.
pubmed: 29569304
doi: 10.1111/imcb.12042
Wang Z, Zhu F, Wang J, Tao Q, Xu X, Wang H, et al. Increased CD14 + HLA-DR–/low myeloid-derived suppressor cells correlate with disease severity in systemic lupus erythematosus patients in an iNOS-dependent manner. Front Immunol. 2019;10:1202.
pubmed: 31231374
pmcid: 6558381
doi: 10.3389/fimmu.2019.01202
Ji J, Xu J, Zhao S, Liu F, Qi J, Song Y, et al. Myeloid-derived suppressor cells contribute to systemic lupus erythaematosus by regulating differentiation of Th17 cells and Tregs. Clin Sci. 2016;130:1453.
doi: 10.1042/CS20160311
Kurkó J, Vida A, Glant TT, Scanzello CR, Katz RS, Nair A, et al. Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disorders. 2014;15:1–7.
doi: 10.1186/1471-2474-15-281
Haile LA, von Wasielewski R, Gamrekelashvili J, Krüger C, Bachmann O, Westendorf AM, et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology. 2008;135:871.
pubmed: 18674538
doi: 10.1053/j.gastro.2008.06.032
Kontaki E, Boumpas DT, Tzardi M, Mouzas IA, Papadakis KA, Verginis P. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. Autoimmunity. 2017;50:170.
pubmed: 28276713
doi: 10.1080/08916934.2017.1283405
Ilkovitch D, Ferris LK. Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules. Mol Med Rep. 2016;14:3935–40.
pubmed: 27574042
pmcid: 5042763
doi: 10.3892/mmr.2016.5685
Soler DC, Young AB, Fiessinger L, Galimberti F, Debanne S, Groft S, et al. Increased, but functionally impaired, CD14 + HLA-DR–/low myeloid-derived suppressor cells in psoriasis: a mechanism of dysregulated T cells. J Invest Dermatol. 2016;136:798–808. https://doi.org/10.1016/j.jid.2015.12.036 .
doi: 10.1016/j.jid.2015.12.036
pubmed: 26807516
Cao LY, Chung JS, Teshima T, Feigenbaum L, Cruz PD, Jacobe HT, et al. Myeloid-derived suppressor cells in psoriasis are an expanded population exhibiting diverse T-cell–suppressor mechanisms. J Invest Dermatol. 2016;136:1801–10. https://doi.org/10.1016/j.jid.2016.02.816 .
doi: 10.1016/j.jid.2016.02.816
pubmed: 27236103
pmcid: 4992618